CANCER MUCOSA ANTIGENS A NOVEL PARADIGM IN CANCER IMMUNOTHERAPEUTICS.

Authors

• Adam E Snook
• Scott A Waldman

Publication/Presentation Date

1-1-2009

Abstract

Employing antigens with expression restricted to normal intestinal mucosa and derivative colorectal tumors - cancer mucosa antigens (CMAs) - represents a novel paradigm in anti-tumor immunotherapy. Immune compartmentalization limits tolerance to CMAs and restricts mucosa-targeted autoimmunity, allowing safe and effective immunotherapy for metastatic colorectal cancer. Guanylyl cyclase C (GCC), an intestine/colorectal cancer-restricted protein, is poised for clinical evaluation as the index CMA.

Volume

3

First Page

14

Last Page

16

ISSN

1611-597X

Published In/Presented At

Snook, A. E., & Waldman, S. A. (2009). CANCER MUCOSA ANTIGENS A NOVEL PARADIGM IN CANCER IMMUNOTHERAPEUTICS. BIOforum Europe : trends and techniques in life science research, 3, 14–16.

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

26855637

Department(s)

Administration and Leadership

Document Type

Article